Varicella vaccine in the European Union


The Vaccine Preventable Diseases programme of the European Centre for Disease Prevention and Control (ECDC) has set up a working group to provide guidance to the European Union Member States on the potential  introduction of varicella vaccination.

The aim of the final report of the working group is to support EU Member States in their national decision-making  process with regard to childhood varicella vaccination. 

To assist the working group in developing an evidence-based guidance document, a systematic review of the best  available evidence was commissioned along with work on varicella modelling. The systematic review was produced  by Pallas Health Research and Consultancy and the modelling outputs by a Framework Partnership Agreement  (ECDC Grant 2009/002) with Pisa University.



FDA Approval of an Extended Period for Administering VariZIG for Postexposure Prophylaxis of Varicella

VariZIG (Cangene Corporation, Winnipeg, Canada) is

the only varicella zoster immune globulin preparation available in the United States for postexposure prophylaxis of varicella in persons at high risk for severe disease who lack evidence of immunity to varicella and are ineligible for varicella vaccine. VariZIG is available in the United States through an investigational new drug (IND) application expanded access protocol (1). VariZIG is a purified immune globulin preparation made from human plasma containing high levels of anti–varicella zoster virus antibodies (immunoglobulin G). In May 2011, the Food and Drug Administration (FDA) approved an extended period for administering VariZIG. The period after exposure to varicella zoster virus during which a patient may receive VariZIG, which had been 96 hours (4 days), is now 10 days (1). VariZIG should be administered as soon as possible after exposure (1). Leer más